DAVID CHRISTOPHER CARROLL
Pharmacy in Oakland, CA
License number
California 74563
Category
Pharmacy
Type
Pharmacist
Address
Address
2
1411 E. 31 St, Oakland, CA 94602
330 Parnassus Ave APT 302, San Francisco, CA 94117
330 Parnassus Ave APT 302, San Francisco, CA 94117
Phone
(510) 437-4222
(415) 624-7772
(415) 624-7772
Personal information
See more information about DAVID CHRISTOPHER CARROLL at radaris.comName
Address
Phone
4835 Idaho St, San Diego, CA 92116
4604 Pine Ln, Lake Isabella, CA 93240
4763 Yuma Ave APT E, Oceanside, CA 92057
Professional information
See more information about DAVID CHRISTOPHER CARROLL at trustoria.com
Sr. Manager, Brand &Amp; Design At Luminex Corporation
Sr. Manager, Brand &Amp; Design At Luminex Corporation
Position:
Sr. Manager, Brand & Design at Luminex Corporation, Art Director/Owner/Freelance Designer at FlyingDogDesign
Location:
Austin, Texas Area
Industry:
Design
Work:
Luminex Corporation
- Austin, Texas Area since Mar 2013
-
Sr. Manager, Brand & Design
FlyingDogDesign
- Austin, Texas since Mar 2011
-
Art Director/Owner/Freelance Designer
Williams-Sonoma, Inc.
- San Francisco, CA Jul 2009 - Mar 2011
-
Senior Design Manager, Brand Packaging
Whole Foods Market, Private Label
- Austin, TX Jun 2005 - Jun 2009
-
Art Director, Creative Services
FlyingDogDesign
- San Diego, CA May 1993 - Jun 2005
-
Art Director/Owner/Freelance Designer
TW Design
- Atlanta, GA May 1991 - May 1993
-
Associate Graphic Designer
Siebert Design
- Cincinnati, OH 1988 - 1991
-
Associate Graphic Designer
Education:
University of Cincinnati 1983 - 1988
B.S., Graphic Design St. Xavier High School 1979 - 1983
B.S., Graphic Design St. Xavier High School 1979 - 1983
Skills:
Packaging, Illustration, Creative Direction, Art Direction, Corporate Identity, Logo Design, Brand Development, Print Production, Graphic Design, Posters, Layout, Adobe Creative Suite, Brochures, Print Collateral, Illustrator, InDesign, Web Design, Creative Development, Visual Communication, Logos, Photoshop, Mac, Adobe Acrobat, QuarkXPress, Branding & Identity, Corporate Branding, Direct Mail, Business Cards, Stationery, Digital Illustration
Interests:
Music (listening, writing and playing), Film + Animation, Architecture, Pets, Science Fiction
Honor & Awards:
RECOGNITION
Global Support AllStar and Nominee, Whole Foods Market
Bronze Award (x2) + Silver Award (x3), Art Directors Club Cincinnati
Excellence Award, CSCA Creative Best
Typographic Excellence, Type Directors Club
Outstanding Intern, Graduating Class, University of Cincinnati
PUBLISHED WORK
Design Direction: A Roadmap to Great Graphic Solutions
International Women in Design (for Siebert Design Associates)
Designer Greeting Cards
Certifications:
CSS Fundamentals, Lynda.com
User Experience Fundamentals for Web Design, Lynda.com
Flash CS4 Professional Getting Started, Lynda.com
User Experience Fundamentals for Web Design, Lynda.com
Flash CS4 Professional Getting Started, Lynda.com
Vp Worldwide Sales At Quantenna Communications
Vp Worldwide Sales At Quantenna Communications
Position:
VP Worldwide Sales at Quantenna Communications
Location:
San Francisco Bay Area
Industry:
Semiconductors
Work:
Quantenna Communications
since Jan 2013
-
VP Worldwide Sales
Broadcom
Dec 2010 - Nov 2012
-
Global Account Management
Beceem Communications
Jul 2006 - Dec 2010
-
VP Worldwide Sales
Mindspeed Technologies
Jan 2001 - Jul 2006
-
SVP Worldwide Sales
Conexant
1997 - 2001
-
VP Americas Sales
Education:
San Diego State University-California State University
University of Southern California - Marshall School of Business
University of Southern California - Marshall School of Business
Skills:
Semiconductors, Wireless, Product Marketing, IC, Product Management, Start-ups, Mixed Signal, ASIC, Cross-functional Team Leadership, Analog, Go-to-market Strategy, SoC
Senior Vice President At Willis
Senior Vice President At Willis
Position:
Senior Vice President at Willis
Location:
San Francisco Bay Area
Industry:
Insurance
Work:
Willis
-
Senior Vice President
Compositions And Methods For Inhibition Of The Jak Pathway
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
7491732, Feb 17, 2009
Filed:
Jun 8, 2006
Appl. No.:
11/450901
Inventors:
Hui Li - Santa Clara CA, US
David Carroll - San Francisco CA, US
Ankush Argade - Foster City CA, US
Robin Cooper - St. George Island FL, US
Rajinder Singh - Belmont CA, US
David Carroll - San Francisco CA, US
Ankush Argade - Foster City CA, US
Robin Cooper - St. George Island FL, US
Rajinder Singh - Belmont CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 239/48, A61K 31/505
US Classification:
514275, 5142778, 5142358, 544 586, 544122, 544323
Abstract:
The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
4-Pyrimidineamine Compounds And Their Uses As Anti-Proliferative Agents
4-Pyrimidineamine Compounds And Their Uses As Anti-Proliferative Agents
US Patent:
7482351, Jan 27, 2009
Filed:
Jun 29, 2005
Appl. No.:
11/171970
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
David Carroll - San Francisco CA, US
Tarikere Gururaja - Santa Clara CA, US
Taisei Kinoshita - San Mateo CA, US
Ankush Argade - Foster City CA, US
David Carroll - San Francisco CA, US
Tarikere Gururaja - Santa Clara CA, US
Taisei Kinoshita - San Mateo CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A01N 43/54, C07D 239/42, C07D 401/04, C07D 239/02
US Classification:
514256, 544326
Abstract:
The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.
Compositions And Methods For Inhibition Of The Jak Pathway
Compositions And Methods For Inhibition Of The Jak Pathway
US Patent:
8299087, Oct 30, 2012
Filed:
Oct 11, 2010
Appl. No.:
12/902052
Inventors:
Hui Li - Santa Clara CA, US
Vanessa Taylor - San Francisco CA, US
Somasekhar Bhamidipati - Foster City CA, US
John Ramphal - Union City CA, US
Kin Tso - San Francisco CA, US
Arvinder Sran - Fremont CA, US
Holger Keim - Irvine CA, US
Vadim Markovtsov - San Mateo CA, US
David Carroll - San Francisco CA, US
Sambaiah Thota - Fremont CA, US
Ankush Argade - Foster City CA, US
Jeffrey Wayne Clough - Redwood City CA, US
Rajinder Singh - Belmont CA, US
Robin Cooper - St. George Island FL, US
Vanessa Taylor - San Francisco CA, US
Somasekhar Bhamidipati - Foster City CA, US
John Ramphal - Union City CA, US
Kin Tso - San Francisco CA, US
Arvinder Sran - Fremont CA, US
Holger Keim - Irvine CA, US
Vadim Markovtsov - San Mateo CA, US
David Carroll - San Francisco CA, US
Sambaiah Thota - Fremont CA, US
Ankush Argade - Foster City CA, US
Jeffrey Wayne Clough - Redwood City CA, US
Rajinder Singh - Belmont CA, US
Robin Cooper - St. George Island FL, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/505
US Classification:
514275
Abstract:
The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
Methods Of Treating Or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
US Patent:
2012025, Oct 4, 2012
Filed:
Apr 9, 2012
Appl. No.:
13/442480
Inventors:
Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Santa Clara CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - San Mateo CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Irvine CA, US
Ankush Argade - Foster City CA, US
Hui Li - Santa Clara CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - San Mateo CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Irvine CA, US
Assignee:
RIGEL PHARMACEUTICALS, INC. - South San Francisco CA
International Classification:
C07D 498/04, C07D 403/12, C07D 495/04, C07D 491/056, C07D 413/12, C07D 497/04, C07D 513/04, C07D 471/04
US Classification:
544 51, 544105, 544320, 544323, 544324
Abstract:
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
Methods For Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug And Prodrug Compounds
Methods For Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug And Prodrug Compounds
US Patent:
2009004, Feb 19, 2009
Filed:
Nov 15, 2007
Appl. No.:
11/940930
Inventors:
Yasumichi Hitoshi - Brisbane CA, US
Elliott Grossbard - San Francisco CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Hui Li - Santa Clara CA, US
David Carroll - San Francisco CA, US
Susan Catalano - Hayward CA, US
Elliott Grossbard - San Francisco CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Hui Li - Santa Clara CA, US
David Carroll - San Francisco CA, US
Susan Catalano - Hayward CA, US
Assignee:
RIGEL PHARMACEUTICALS, INC - South San Francisco CA
International Classification:
A61K 31/5383, A61P 35/00, A61K 31/675
US Classification:
514 81, 5142305
Abstract:
The present disclosure provides methods for the inhibiting proliferation of tumor cells, and methods for treating solid tumor cancers in a subject by administration of 2,4-pyrimidinediamine compounds.
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
US Patent:
7858633, Dec 28, 2010
Filed:
Dec 6, 2006
Appl. No.:
11/567276
Inventors:
Hui Li - Millbrae CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Sambaiah Thota - Fremont CA, US
David Carroll - San Francisco CA, US
Kin Tso - San Francisco CA, US
Vanessa Taylor - San Francisco CA, US
John McLaughlin - San Francisco CA, US
Mark Markovtsov - Foster City CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Sambaiah Thota - Fremont CA, US
David Carroll - San Francisco CA, US
Kin Tso - San Francisco CA, US
Vanessa Taylor - San Francisco CA, US
John McLaughlin - San Francisco CA, US
Mark Markovtsov - Foster City CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 239/48, A61K 31/506
US Classification:
514275, 544323
Abstract:
The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
US Patent:
7868013, Jan 11, 2011
Filed:
Dec 6, 2006
Appl. No.:
11/567506
Inventors:
Hui Li - Millbrae CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Sambaiah Thota - Fremont CA, US
David Carroll - San Francisco CA, US
Kin Tso - San Francisco CA, US
Vanessa Taylor - San Francisco CA, US
John McLaughlin - San Francisco CA, US
Mark Markovtsov - Foster City CA, US
Ankush Argade - Foster City CA, US
Rajinder Singh - Belmont CA, US
Sambaiah Thota - Fremont CA, US
David Carroll - San Francisco CA, US
Kin Tso - San Francisco CA, US
Vanessa Taylor - San Francisco CA, US
John McLaughlin - San Francisco CA, US
Mark Markovtsov - Foster City CA, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 239/48, A61K 31/506
US Classification:
514275, 544323
Abstract:
The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.